IL6R and rheumatoid arthritis: Similarly, in RA, although combination of MTX and anti-IL-6R such as Tocilizumab has not shown clinically relevant short-term superiority over Tocilizumab monotherapy [44], concomitant MTX treatment with Tocilizumab may have an interest in low Tocilizumab responders first under monotherapy.